-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Jl48BgRWm/1iaOSVWEHHHFF8ZI7AGO3LlTgVe1kMEVFWUalR5eP1wf5cDs+H1Q4C
 MXY/uI42wWF9mihTukFq2A==

<SEC-DOCUMENT>0000950123-10-097186.txt : 20101028
<SEC-HEADER>0000950123-10-097186.hdr.sgml : 20101028
<ACCEPTANCE-DATETIME>20101028110305
ACCESSION NUMBER:		0000950123-10-097186
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101028
FILED AS OF DATE:		20101028
DATE AS OF CHANGE:		20101028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		101146860

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o66118e6vk.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>Form&nbsp;6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Report of Foreign Private Issuer<BR>
Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>For the month of October&nbsp;2010</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><b>Commission File Number 000-31062</b></DIV>


<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Oncolytics Biotech Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into English)</I></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B><BR>
<I>(Address of principal executive offices)</I></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F or Form 40-F.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings">&#254;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;<FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;<FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country
exchange on which the registrant&#146;s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant&#146;s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->





<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>EXHIBIT</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>NUMBER</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="LEFT" style="border-BOTTOM: 1px solid #000000"><B>DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">News Release Dated October&nbsp;28, 2010 &#151; Oncolytics
Biotech<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Inc. Announces Cdn$25 Million Bought Deal
Financing</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><b>Oncolytics Biotech Inc.</b><br>
(Registrant)<br>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:  October 28, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/  Doug Ball
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Doug Ball&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>o66118exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="57%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o66118o6611801.gif" alt="(ONCOLYTICS BIOTECH INC. LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">210, 1167 Kensington Cr. N.W<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Inc. Announces Cdn$25 Million Bought Deal Financing</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB &#151; October&nbsp;28, 2010 &#151; </B>Oncolytics Biotech Inc. (&#147;Oncolytics&#148; or the &#147;Company&#148;)
(TSX:ONC, NASDAQ:ONCY) today announced that it has entered into an agreement with a syndicate of
underwriters (the &#147;Underwriters&#148;) pursuant to which they have agreed to purchase, on a bought deal
basis, 5,440,000 units (the &#147;Units&#148;) of the Company at a price of Cdn$4.60 per Unit for gross
proceeds to the Company of approximately Cdn$25&nbsp;million (the &#147;Offering&#148;). In addition, the
Corporation has agreed to grant to the Underwriters an option (the &#147;Over-Allotment Option&#148;) to
purchase up to an additional 15% of the number of Units sold under the Offering at a price of
Cdn$4.60 per Unit, on the same terms and conditions as the Offering, exercisable at any time, in
whole or in part, until the date that is 30&nbsp;days following the closing of the Offering. In the
event that the Over-Allotment Option is exercised in its entirety, the aggregate gross proceeds of
the Offering to Oncolytics will be approximately Cdn$28.75&nbsp;million. Each Unit will consist of one
common share of Oncolytics and one-half of one common share purchase warrant (each whole common
share purchase warrant, a &#147;Warrant&#148;). Each Warrant will entitle the holder to acquire one common
share of Oncolytics at a price of Cdn$6.15 at any time prior to the date which is two years
following completion of the Offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Units will be offered in Canada by way of a shelf prospectus supplement to a short-form base
shelf prospectus dated June&nbsp;10, 2010, that has been filed in the provinces of British Columbia,
Alberta, Manitoba and Ontario pursuant to National Instrument 44-101 (&#147;NI 44-101&#148;) and National
Instrument 44-102 (&#147;NI 44-102&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oncolytics intends to use the net proceeds from the Offering to fund its ongoing Phase III
combination REOLYSIN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and paclitaxel/carboplatin trial for patients with platinum-failed
head and neck cancers, its other clinical development and research and development activities, and
for general corporate and working capital purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The transaction is subject to the receipt of all necessary regulatory and stock exchange approvals.
The transaction is expected to close on or about November&nbsp;16, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The securities to be issued by Oncolytics have not been and will not be registered under the United
States Securities Act of 1933, as amended (the &#147;1933 Act&#148;), or the securities laws of any state of
the United States, and may not be offered or sold in the United States or to, or for the account or
benefit of, U.S. persons (as defined in Regulation&nbsp;S under the 1933 Act) unless registered under
the 1933 Act and applicable securities laws of any state of the United States or pursuant to an
exemption from such registration requirements. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Oncolytics Biotech Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of
the human reovirus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company&#146;s expectations related to the pricing, timing and placement of units, common stock and
warrants; the Company&#146;s belief as to the potential of REOLYSIN as a cancer therapeutic; the
Company&#146;s expectations as to the success of its research and development programs in 2010 and
beyond, the Company&#146;s planned operations, the value of the additional patents and intellectual
property; the Company&#146;s expectations related to the applications of the patented technology; the
Company&#146;s expectations as to adequacy of its existing capital resources; the design, timing,
success of planned clinical trial programs; and other statements related to anticipated
developments in the Company&#146;s business and technologies involve known and unknown risks and
uncertainties, which could cause the Company&#146;s actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties include, among others, the pricing and
completion of the contemplated offering, availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely
completion of clinical studies and trials, the Company&#146;s ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties
related to the regulatory process and general changes to the economic environment. Investors
should consult the Company&#146;s quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on forward-looking statements.
The Company does not undertake to update these forward-looking statements, except as required by
applicable laws.</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>o66118o6611801.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o66118o6611801.gif
M1TE&.#EA)P%'`/?_`+.RHFQK4=O:TOW__-+1Q82":___^IN;F]74RH>'A^3D
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M]?3S[6]O2>KLY&MK2\_/P;_`KX"`:*JHF&9G2____?_]__W]_?___/S\_/W]
M__S\_?W\__W]_/S\^__\__W\_?S]__S]_?W]^OS\^OS\__W]^_S]^OS]_/S]
M^_W\_/W\^__[__W\^?_[_<3$K__]^O/SZE]B/GQZ9W=X9GAW:/S\X_?W[_'Q
MWF]O4./DU^3CV??W[./BW&QM3]C7T(*"7L/$M=C8T&AH1I*/;?/S\).3D;>X
MJ=O;SM[=R_SY_X.#?=?6Q?GY^:BHFX^/A>SKZ];8QW%R2?KY^KVZK\_.O?K[
M^L_/OW-S3GEW3?_______R'Y!`$``/\`+``````G`4<```C_`/T)'$BPX,!<
M!G(-U*5+(,.'$!L6Y&4@H<&+&#-JW,BQH\>/($.*'$FRI$F,_TX*I&B`UX!<
M,',->%FQ)4&8*G/JW,FSI\^?.U.*#!'B9L4!1),F'9#%YD"B0*-*G4JUJE6!
M0D'F*O&2H,2,.`_.O$JVK-FS9K-RW"4P&(ICQY2%]:@P6+"Q`MFBW<NWKU^.
M:C7V&CSXWJ\7`VV$"P.#A>/'CJ\0*%.-(!%=OPCK_<NYLV>K@3/N.K.KUYDA
M`E$1N%4`#QXD$6++CHU$#8\1H\AL\>!O"&G3FS\+'TZ\9&B,I7_]$KAFU#4(
M1Y*`820J`I+KL&53$I%D28-K\WKP__*W*W/PXNC3JR=X_.(OO6MFM)""PX28
M)!&.Q(',XHI_%B(<$8$8]<72C2OA"#38>@PV2)Q0N?`BX7C^#(!",,5DZ`\4
M'12!1!0X\/`#&C!(0,LC"ETD0!@C``+!+"*`X0(:`%C"RS(#&&-7BA/RDJ*#
M0`89%80QI7@,"KVT$4(NE4"P1!0F\("''I-8@L)&1?GCAQ\]P(!'$B)0$H$<
M!/B3"S/"Z!.,0$7^*.2;<)[TCYL$-=,+:OX,PD,2130`@1Z+9.&/`<>4=]Y3
MS)"FT"L$R!&`""(TT,@@L/C3BP:'LAGGIIQ^]`^%!N7RBRY[7&$")3B0`$,7
M"AF`PAF]$/]!1$:^^/(+,8<9X,\E'4C1S1136,%$I1H`<U&$G2:KK$&?(K=K
M`4<P$D41DZ13H3#!&#/K+AKX0JLOP``3PB_"^,/+`I%8`>D23*1!WK&@+BLO
MI\WFM=R.:^0103\N0%!FA4K1]512_H2@`B1.BL"N%OX$LXNM>B$[[\1QUBN0
M+\(<PPL(=R#13Q1Q(-!P,`1'."%8+8&:U"X*>:$*'B+\$(<6O!PCC+=LQDOQ
MS@W.2=`N?ESI1@,XQ-("PT.06U"1&L5D4&;'Y++-"`U,P4D@_J#@1W!T\NPU
M>FH-L,Q;DP1@'P2:Y*)M+\)$M)!'$>WR@C[-^+,`!%.84,0"S*#_T,P`7P?>
M\X^ZR(4`*":8T,@X%3:CS#'!N.T0W!#MXDPQQACCCR?JX@&!-[RT/9#.@I?.
MV3^Z/F1`%@\TP(@4M/@#C2X4Y9*E3E_IDHL-5(O`PPPA//-0[:87?[I"#.6B
M"SQXF)`$"X\,,P3MNM[N4[GP@"*"WJ:,Q]`+NAHO/E]")0_"%3R8<+0_Q&@`
M?NH]A74&"J\`P(,(W12PC?(/C>__62E)GC_@4;4C`"`7PB""-*AADZ_DY&3^
MT,"L:&`+,<1L$/Y@R/\V6)9_A"!<+P#!`V8AA@G8(!?$&,;[D,>3`50$>2KT
M1P5,H(9NJ,(2_@`&,;K&P1[VY!_Z((*Q_TS1#1PT`&NC\]%/!D`1[VG0`#F8
M!0ZZ48%<#*%;/LSB3_ZQC%_X(A@;*&(#*L"FN9B))T6I2/^*4H$6\(,'0>`%
M$9*Q'"W:42?_R$0-B&&`._`@`E?``O7B]<*=$*5V#"$*,?SQ`"3$@@7^.,,O
M`'?'2IHDCP[PAR:*H(99V"&',Z%00PJI$Z)$2'D%`UPNKM"-)-CB&Z-AQD5>
M(*$?.4T@MWN!0JQWQHMH\&T#H61'>(D1,X;*33P\"#+I%!/O9=",#MR(,0NB
M2VF>TB`L6UK78$),B2CQ*>P90$.><`X<M``*!]%F5>22@C^80`KY\`<=&^(C
M70R!".,!U2Z.X?^`963H%S7@929>HKKQ$*49S%"&)$@WD!+@Z!=+&DBM;`4,
M#6@N(RWI!3.:\9:.*,F%WS1(^`:2!12T;7@E0,$<RG60$OP-&0SE2);J><]X
M`6,F2](%,))QC`M<(!C)`,8P,%J".2`I8BUI0S&$L0S$.,26.3)&#2[ZCV9H
M;A`N``,$<-B7`03C$K8P@2A@<(]<:$!W+;$G,4BA"2"8PAPH((('D"&,&F"N
M!OH(AR92D((M#)1_M#-H,6J@`8&4(@6F,`4[`+``4\!#!0.9Y(]\001G%%8@
M?`""6Q-K"LV:(@LPJ4%%ZVB0>Z0`"/60!1%"X,)DFJL,"!"`.010D9O_,41"
M8LLD6]E!``5HE!G4@`5B.7M:SBIVMNS0;`H08`0S)42M4-BK)O9`C&64(`0M
MH2PR^.D,B=0!`;.5K3G&<0F%Y,(/R/"B<VWVHS(``1ZN8$$3!#".-PRD!C7`
MRC)\@0HF)"$6D"!$K?@B-G^,(CH%>$0$?8&0\>Q"%Y@@P1^Z`0I(Z`I7;W%`
M,"[P#E#\`102,%<&(7*Q61%"`DP(P`\^D0%.<"(#&;"%'JX@@X9-]@S1H$86
M5&"&$5B!!"1X,2=(\(D?L(`!-A#($'!F$">\B`23.$@T;R(#"/P@`'\@PZ`<
ML`O6#L`7#?D&&F9AA6P4(@1M6(X`!`'D-F=@_PG=$$4WVMQF08R`"LY5"#%T
M,0H)D\`3_BA!"0:EJUX08PC&8H4*`H&&'PR9$U;(`!U:D`,?!($>I$EB+BSA
M"3WD0!R?L$8LQ$$'$N#"%4'P@3Q8$;Y_#-H)C9#1#G)1#":?91>RO(4+DJ`*
M$)0'K0;(C#_(`(HI),$$`0C"E7IQI#09(!!5"T#L`.<V7:PN#$SX,`0>\(0G
M!&(#&P!`-@ZA!U1$`QD_REA%[&`"))#@#MWN-K@G\0!!@()&=<@%-4+ECRVT
M(`HNZ(17-F**(E!"#7_`1"X<@12D-$0!:(@%$FQAB%SHHQB_.$8=,$&&CC\!
MW`^(`!@FP(`GD,'DF/\`@,B<RXM?S,H3Q3X'`/QQ#'%6)!C"2`9JNC2%631`
M#C,(A-`WT`H?>%@'^D!&,'ZTBQ[(H0&S^-TZ`$"`!3!@`ZH01P,J7!&L#'H+
M<C#!$=S@CV(0DRR^*,HMHJ,*5E3(N0;8!<O(8#9TA((2/X#$E9XA*UUZ0PQ@
MX,&_E,B081"#%UG8P`^V/@,H5,$@6Y"%2H]A$8&4H"F>^($H\H`//!MD&[?`
M1C=FT8).6&0S"K%$"V34BC).F2#,R`40BB`&-00`$RY!BN8,@88&1"`/:\@:
M,KQ*>8.\(!"@4(,M!&408R$D[FNRPQ)PX`(&O(MZN4"&0!`1`"0<`0^TH,?_
M1;ZP!;$)(SB7F$(WQ)"'1&A3"RJH`RD,\,M_`,X2<@##$L@.E;VDW1\=P':O
M\';/ARP;(`5XP`(;T`_\\`-!H`^](2O^L`AXP`B"ES/*TS["D`N=@`1B4`3Y
M4`H.06(K(6B5MPO+\`AVD'S=$$^]H0M$X0LZ)Q#Y(`[X4P0J8'&]$#'^8`,M
M('9DAU;"9!"^T`9LP0YR(`K(=D`#P!;>,`$2!PCHQ!)=IPO#<(6_!'-X8`O@
M8`!,E'M048#C80=2Y`('5'@P,1H>T`<-D`24D`/?H$PP`2H5H3-EX`*,(`:`
MD#K#``U#0$>]-`"DY4$].`%@<`1P4#!G=Q50$8!)_P`(`U@4#79&&S`+ZJ,-
M+'`.,1,$T>`/1.`M%!@E_U(A7W9/_E`+`:`&#6!A381;,_&*KZA$K"5#/Z`&
M>G@!OI`T`R!H`]`,SD`$+[`-KO`KH/`$-'<&9\!D8&<"^_=,I&00XS($J+$(
M+<`#4Q```.`CX1!QL5``>Y!!YE(3(P:#!)-Y8F`+VU!V29$*J2")%J$09"@"
M9CABPP`3.T0#20@&H<`-O9%V2I$4MT00Z7`%5M`-+3`#*@`+(V4FR[`,#C!5
M./,/Q>`/JB=VB8@7:`$5:_>(D6@F(56))<0&*N!'./`#>O`*N=`+_M`%S7.!
MJ?1EP-`0+"`%10`*E7!&+/_1%'7X([+(1)W0`"(0`?)@`,`P!+F0!1<P!P,P
M!_H`#,[@#W:`"U/0`#Z0#LM0*$SF!#\X"T&($*Y%'D3P"V<P@7+0#0K3"M[0
M>TB@"CDX/0WA-/1D.[-HCGG`!EE0`A0A:%SAD3\2CP;D#R]P6[PP5`0P!=M3
M!$DV/2+Q"`!P#;-P#BW0`D'@!940!J\0/LF0#&V0#%@QD:JG?Q<YA&8Q%AL)
MB07#EQKT!#_`#Q.P!?ZP!P6`!`ISD@K!DB*`!&6B"[N(%,;2!46``XP``;&C
MB$ST`L89$;2S2X-"-8P0"^V00RKT0KI@)]*8"SO``XR``WA0<7%'$)_)E>`8
M4P/_\0S\-%4KV0(18`)3,`$-L`0%`%F[8'8C"'?TIRF>L`3L!PZY\`(J1$M*
M=$K)DWD!8GUJI$:Z$`0_(`(!X`EG\)#C.#R\\$LYPPMKX@^R``!H8`4_(`4N
M%@$C,`)PT`2Z8@#+@!6`XV]`Z`]_0V"`4YH@T#!>AA0*00:U.`&5X0]U$`FS
MH']Z<"44B`/B0`#*LXO7Y2VTH"Y(``/["0P9(FC(>84J]",&P`+=T`\1L`D&
M0`2(!A-66`*94`S&P@V&*`)_H`"YH`R\L!E.$`I@(`5N@$HFTR,38EXN$0(8
M<Y[=("UX``A)1G^V-A`[N1*;@Y_HF$,:=$HQ&E'W.04__S!S%F$`+[`FD#`+
M4P`*BN`/S)`)^VF<QFDRAUH3"5$:SR`0I"`!+J,*Y.`"G.`=>'`%'5`%*?(/
M<^`/L':(&%0#F<`7>N0/:V</=^!KP_>*(8`83[`$:C`![F(LLA`)2&`"H*`'
M65`!>`"DN;F;8.H/I%``%G0-%1`,6DHNQZ!+5.@CF]H0@`,$>2H*<9`%+S`$
M+U!4U!`,)5`#;8`:\=@`5T`%RK!=!*&5)O`#9)<+:3<`NL2IS10ONZ`,@]8%
M$Q`%O/:-:?5Z*\$CF_,#YZB?8"80-0&+PSJHC#IS3@43PA`",T"I`6",QE`,
M+]$F^_FII$0$E[)(9E(%K%`')O]W!TL`!DAP#CY@7_[P#X62#OX5`0'&#(MH
M%2&07W:P:PD627>1%(BQ`4M@`M>0!KDP#,:2HU*4=^V`-P$@I"\9`D,P5'J@
MB5:P`_[P#$6):#E3$Q,2F&_'#@&``TF`!I!%!$LY!UG`"[DHC5"952X0"+J`
M`ONZ&?Y6DF2GB"%@A?V#@00A#`Y0`KG`!**`!$%@7I6'$4XD$)GG2OKY8&4D
M$TA!%(@A?0%RAFQB`&MB"!#`#TE0EZ(B$KG@``[`#%^6##70%0*1#JU@`HQ@
M`G^09#^[@[F`58Q0!#ATM%41`KMP"7D`!F/E![TA$XM;C_ZP`4=@`LB:0Q;5
M;Y'@`B+_H`9V4`37^"^BFXM$8``",`%*6`"8H"O2,SW^^!0-`;>L]09!$`!%
M\`,=,#"+*XU#$`):D`=)@`-2@$'"@`S*8+@MH`8_4`N**TXDF#./BPS(D`64
MBP1ZD$&[>;2\D!0-<9^>FPN@2Q!U:H7P&"U'8'V)U%H8\P3=P`^Q,`/,9SO!
MI$SCJ+'F0B&YF)G%T`:CF@C;@P=WX'E904Y@T`*0U1=%`00-``:S<`I6!`S(
M8H4"$0A2H+U6ZPL9`H$VP*R<)`(X\+7-E$'`(($5,`&@L'4,4`TB.!'IH&`%
M*Q&]P`LH$`2@,$6U\*(7L0T,P`/=@`L,X`C8HL#]VL`GNQ&@_V(R)+R#O1`,
MKD`)+J`'RN-EBRBZ_><)4A`%7$C"H>(]UKNTC%!](\9:7#&1_M`*LR!Q+(``
M,EL0J``+%\"EA^H//0`%-$`%3E40:Z"M8I`!@R`1_P`,OY`+FV0"+O!)?VH6
MJR0*(B`.L5.45>P+BQ0(-:H%X0.0=7`'<XL#8SR<A*<Z(5`&>O`'*M8"/E`.
M9K`#T[`#9I`#?Y`-"$!Y/T(N%1$$2"`*,C,-9E`)7N`%9M#.JG!E=Z`("8&F
M.N.#4<`($]`)Y?#0JS`-J[`*Y:`(YD!7R1BG;H(.$I<#&<1:_1<JO#B7/^!*
M-)"F?UK%NJ"2=B`%(C`+,T>.,[&7`O]1"2,P"Q+F`P!M!CQ=";<``7\P#U00
M#*3A"\K@#XI``A`@!XV0`Y40T&;@!8C@!8#`"3]@"V10!93T#\1`!,K01Q$0
M"P^`!7VQ'(TD"DQ``P-P&H$E$+,"`'0`"A"`S1NHB`+A!".`"[&`TR%&RXVK
M%UW@`WF-"Y_`8C!&`G%P!4R@!TXP%\FP"RC`"ZSP#6Y0`"1`!Z469)B=`;@0
M"7U0*7O&0TX@!BZ`!"X`8YA-!QE0V()P""FPUNKEN`)Q!R\&2>0HH4MS%&,Q
M"G2`"]A``R3L+=^4G&X-@'00`'0P"HH;(08@N1)!`ST6`"0`8ZA-!VKP`#`P
M#X8P`,CPR"C_8``=P`0/\``M`&/6X&*HK08L``/>X`^I@,K_0`3GMPMD\,0\
M4`9^T491(`Z0D#5W,DBY<`;.H``F0@!5P%XVX7(]N`#Y<`H+8`-V,8ZH%`+%
M@"F#P@?YL`^TH.$;3@#,!YC5E!=G$`S/@!BZ8`0?T`,]0``S8`8;G@_YP`9F
M(@S$L,P"00@$(`'[L.(\3@`;3@NT0`".X`>P<A/?E`OC`.-=T`NZPPMPJ[D3
MT@PE4`8+(`$(X&O&LL,.T40!_@SA8"(+$`XO8`Q+HCS4*Q`RB^$2H.)KW@,+
M4`;/5U+=O4]^X",^0N4$T`-!P`($<`J;T`Y-<2,UP%+_$#2R)`!/_QP+QM@7
M0>`"_=``^.T`R'`9[V,`L4(0:\U@+Y0+#;DT.#*.75=V%N4'T1!37E4#89E-
MY%$:IJ$!CUT0"VDNPL`VD:U-XFD0O``K.WBHM22'HU(13^Y+;UE@`Z$,M\(R
MA:0+E7[I!`%1Q7F%OK";.J<[&7%^A*)TI%$>OU!1J,PFHPJHP2!!DK!O/_L"
MRF"T\0`#2%"W3N`/_CB)/U$[3%8&:B!6@+`%$>*MREX3NT`,,=EE\V0F"K&;
MH^(+0Z6B!,40-L%:J:`C_&E/B.8+Y<%:?],+QJ"[J[X+%\\,UN4`@../0C5@
M7J2PL7Y*NY`,7R2L+A28#U$KNQ`,LA2Z%/_BA_WN+<`NL2.&2Q?E+8;"8+V^
M[Q71[__>"[]@#+N0\##8P2BO"[N0>PWI\:_(9#LX8+8K##-Q%PKA"\:P'%8X
MMM(@S-[D#PCP!U-@AKF@F2IKH#P!]`.PF<EP!CG@`J$0`!"<.CAO27BO$?_@
M3><%`P$0!2U0&<:@`:SE3#MAKDC1!JLEK6#0#8#0A5^9]Y*/$C<A]@U@`MW`
M`MNP"^*BO">1%!HPEE$D`E:P"IXL\).?^AOQ*81WE#!01/#$/C(MFB>!4XL+
M@YLP!5/D`\"=L<^H^L`_$*AC$;K@+0A0TF!0!"*C4[Y@NSR!4.`R5&'0`*X+
M`17W8*.4N6PQ#QC_<`/>+P0*L!;^\`6'\`$>40@?H`[>_P%GMH-R5Q#O'P/>
M3P$80`'>7PB6HA$?@`'=#Q`W;G#PM\O?080)#=+[H(["P!`))2+402%B+W]*
M,.B8V-'C1PX89$3\:%`=%QD(/V`P4G(71G\R*MX0@L5?+X,>=^W<>?`?+Z#^
M?!$1IJP5#S!X(&CR1^P7LV8?I7Y<QHS("W\+_I@P4633,12_?.GRQ\M`KH0A
MN*R00<C(#0L?7!H4LD+)U(('5E#XH.#=C14G>IW!*;$73B,*%!Q:P>&2`D*#
M<W8\L2(&(4)8C!R>+'%7"!D6W@GY<&DS7KT(0Z@+C->U1,!WI6+D8H%+_P)_
M9]9^*4G8`P4,[PXHN!0/9V>%/`O[^W>0UX`0OLX\\^>FP90&<K3X$R9LV6O7
M`Y85]4=C!(\I5C#EBG;&%\E<O!3ZP[`BP8D#%BR@^LC97]T82/I(AQ4L:`FA
M^N0Z3J$S)@/P()ZDXJ`Q_$[PX"6I/E@!`\/PFO"0`T*L[P3PP*M+MI+\X>*&
M&#94<07>.MKI#']8BT&A"Y%32#*$_B%K@!(&R.078OQAY0X>1#`A#@3\"0:K
M$J<*1KXP5$DBE!_BV&(89WHI)@0P/5KK`"64F&<%+FR2\8PS0@#LQJGHP<""
M&`^B8`6YV)2(,)[<M"RWPV#J*`0E+(LA!HXP_/\H-"[HB7)"#B+E@#$2H\3K
M1->XP&"7&"R@8,(Z#1LL!+WFF>C"%"7RT1\@EZE!%V"`><&0/)#H9Y9&"#@(
M+8F"\B@78"6*[Z!*_I@E%!?B2,.?(8#9I09CPNRH/AV^4"*!V^+1"<-W[')M
MC+T2:"(!(;@@Z)>7.DNW,$QYTC&ARBB0EX(#%)71GT)LHT"'$X10`+45$DJ@
M,4OQ>C-3#D,X@P(+8-SVIA#J^BL&#H0HI*"2)NYQUV`1PFH-6\[!00PY6JG&
MGQ!^*<878YB9XP(#=)%Y9ID-F&,98Z)M@YD2_#%@D`9,$$$*)I;UQ36#"J%`
M""$X:.)`O-Y*:;F/C&C_X@/2QOD7Z5VD!D\&X#`0^P",I0H!BT(XN$&))@AQ
MR1^L$U+B';<%+5BB$#A(@!![.])`G1,4?8<"_ERCIPFUV5;SH[PYH">GYCY2
MQA\5KL!#C"DX>:`"M'(!9HAD>@DF&&!+'V"`7(XI`1ECT#W(`$T>P$.-*4A@
M@@9_-#CZ[IM*',SNU]Z=R%[AS8ZH^+MW:;`_&GG_B+#94,8)^.2+GPSR_I!!
MQA]=^OA##$9$@<"'1;(X"!AWA@!S??8'(.8JM/Q`X(H_8L&AFT842<<?(E#%
M:]WI!2IX@4+>COSSO^/TQ#5\.DR#%H27`!:/,U0[2*`HZ+P*2D9X.TG@2]A4
M_\`,'B8W%Q+AMGH1#^QY)!B]^,40AN&//D``"?PP`0_PX(,4@``%4R&+/T#`
M"EH\H`$1P`$_9M$"7?D#&+WP`'40J,$9-0^!RJ/>MJB(-,)<4"H<S*(`D3:8
MY7GD@Q?D21@QB!`N2M""Z3*C5,;HP0_JQ`,6]$E)Q`*,8;R`%RJ8@1R0(`81
MS*((!6#"`KXAE2:$802J$(.MP.`"-`#`!KEXP3"<M0M>?=$@FP2/NX+GR4_V
M;2J>[`D((<09Y('RE`H\(QH?F").%L24$')7A.8RF<A))1<&B`8UT**`#L@A
M:$G@!P_.,0$6)%.9RRS"#[J1!!R8(`(-8$(9R@(67_^U4IO;Y&8WO?E-<$HE
ME[\R0!:.$0TB#.$@AKC#-:8@!7[@0!01H&<]ZQD+>_3#'B[HAASFT0.T$*,7
MRRA!"0S`BTR&4Z$+96A#'>J\<>+M=$`)AGN(H0$/^&,;5"#`#`#1#3P@(0)(
M(*E(Z8D$$XAC!*,@@R7\T!0B[,(8^C#&1!'Z4)SF5*<[!6=$$W*Z`7#O%[\0
MA@.:88PO(<0&X?`"#*ZPS"M$%08]*`05>#4`!RP#!2A@81O`%)^$\E2L8R5K
M63?VD80>S0#0`=/1>O@:LNSB=`:@JU`$%%:SYE6O>_VF3_GZ5\`&5K"N\>M@
M#7M8Q)JUL(EE;&,=V]/'1E8GLI,]XS\L>UG,9E:SF^5L9SW[6="&5K2C)6UI
..37M:U*96M:M%;4```#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
